LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical ...
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc (AGEN). (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results